Clinical Trial Update: Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens [Phase 1]

View source ↗

Summary

A Phase 1 trial of a cytomegalovirus antigen–targeted peptide vaccine for glioblastoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• CMV antigen–targeted peptide vaccine (CMV peptide vaccine)

Snippet

Sponsor: University of Florida | Conditions: Glioblastoma | Phase 1 | Status: WITHDRAWN